Frontiers in Health Informatics
ISSN-Online: 2676-7104
www.healthinformaticsjournal.com
2024; Vol 13: Issue 3
Open Access

Use of Electron Therapy Device eMedica in the Management of Chronic Lymphocytic Leukemia: A case report

Dr K. Rajashekar [1], Dr Hemavathi Patil [2], Hemant Rohera [3], Dr Ramesh Chouhan [4], Dr Deepak Nagpal [5]

[1] Assistant Professor in Department of Dentistry, Dr Patnam Mahender Reddy Institute of Medical Sciences, Chevella, Ranga Reddy District, Telangana,
[2]Associate Professor and HOD, Department of Dentistry, S.R Patil Medical College, Hospital & Research Center, Badgandi
[3] Director, Research and development, Rohera Healthcare Technologies, Pune, Maharashtra, India
[4] Vice President and Dean of World Academy of Medical Sciences Netherland
[5] Ex-Dean, Professor and Head, Department of Oral Pathology and Microbiology Swargiya Dadasaheb Kalmegh Smruti Dental College and Hospital, Nagpur, Mahrarashtra, India
deepaknagpal2013@gmail.com

Cite this paper as: Rana Jalal, Asmaa Ahmed Hatem Sultan (2024) Pathogenic Bacteria and Skin Infections: Pathogenesis, Treatment, and Prevention. *Frontiers in Health Informatics, 13* (3), 2701-2704

Abstract

Chronic lymphocytic leukemia (CLL) is a hematological malignancy characterized by the accumulation of functionally incompetent lymphocytes. Traditional treatments include chemotherapy and immunotherapy, which can lead to significant side effects and impact the quality of life. This case report describes the application of a Electron therapy device, eMedica, as an adjunctive treatment in a patient with CLL, highlighting its potential benefits in symptom management and overall well-being.

Keywords

Chronic Lymphocytic Leukemia, Electron Therapy, eMedica, Quality of Life, Complementary Treatment, Symptom Management.

Introduction

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, with a variable clinical course. Patients may experience symptoms like fatigue, lymphadenopathy, and increased susceptibility to infections. Treatment options often center around managing disease progression, but traditional therapies can lead to adverse effects that degrade patients' quality of life [1-4]. Recent studies have explored alternative modalities, including Electron therapy, which utilizes low-level electrical currents to promote cellular repair and reduce pain and inflammation [5-8]. This report examines a case involving the use of the eMedica device (Figure 1) in a patient diagnosed with CLL.

Case Presentation

A 68-year-old female patient was diagnosed with CLL three years prior. She had an asymptomatic presentation that progressed to symptomatic disease, characterized by severe fatigue, lymphadenopathy, and recurrent infections. Previous treatments included chlorambucil and rituximab, which resulted in partial remission but were burdened by significant fatigue and other side effects.

Upon presentation, the patient expressed a desire to explore complementary therapies to alleviate symptoms and improve her overall quality of life. After a thorough evaluation and informed consent, the patient initiated treatment with the eMedica Electron therapy device alongside her conventional chemotherapy regimen.

Treatment Protocol

The eMedica device was applied three times a week for a duration of six weeks. Treatment sessions lasted approximately 30 minutes, focusing on areas associated with lymphatic drainage and energy restoration. The Electron was set to stimulate cellular activity without inducing discomfort. The protocol aimed to enhance circulation, reduce inflammation, and promote healing.

During the treatment course, the patient was monitored for hematological responses and symptomatic changes. Regular assessments were conducted to evaluate the size of lymph nodes and report any adverse effects.

Results

Post-treatment evaluation at the six-week mark showed a significant reduction in lymphadenopathy, with the patient reporting improved energy levels and a decreased frequency of infections. The patient's fatigue, as assessed by the Functional Assessment of Cancer Therapy (FACT) fatigue scale, demonstrated a reduction from severe fatigue (score 20) to mild fatigue (score 34).

No adverse effects attributable to the Electron therapy were reported (Figure 2), and the patient found the sessions to be relaxing and beneficial. Moreover, laboratory tests indicated stable hemoglobin and leukocyte counts without significant cytopenia, suggesting a favorable response alongside standard treatment.

Discussion

The results observed in this case suggest that Electron therapy with the eMedica device may offer a beneficial adjunctive approach to managing symptoms associated with CLL. While the underlying pathology of CLL remains unchanged, the emphasis on symptom control and quality of life for patients is vital in chronic illness management [8-10].

Prior investigations into Electron therapy suggest its potential for promoting cellular repair, enhancing lymphatic drainage, and alleviating pain, though larger clinical trials are necessary for definitive conclusions. This case adds to the growing body of literature supporting the exploration of adjunct therapies in the management of hematological malignancies [9-12].

Conclusion

Electron therapy with eMedica appears to be a safe and potentially effective adjunctive treatment for symptom management in patients with chronic lymphocytic leukemia. While individual experiences may vary, this case highlights its role in enhancing the quality of life for patients undergoing traditional treatment modalities. Future research is warranted to explore the mechanism of action and establish more extensive clinical guidelines for broader application in oncology.

References:

1. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood. 1991 Oct 15;78(8):1901-14. PMID: 1912574.
2. Swerdlow, SH.; Campo, E.; Harris, NL.; Jaffe, ES.; Pileri, SA., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Vol. 2. Geneva, Switz: WHO; 2008
3. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005 Feb 24;352(8):804-15. doi: 10.1056/NEJMra041720. PMID: 15728813.
4. Ponzoni M, Doglioni C, Caligaris-Cappio F. Chronic lymphocytic leukemia: the pathologist's view of lymph node microenvironment. Semin Diagn Pathol. 2011 May;28(2):161-6. doi: 10.1053/j.semdp.2011.02.014. PMID: 21842701.
5. Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021 Dec 1;96(12):1679-1705. doi: 10.1002/ajh.26367. PMID: 34625994.
6. The Surveillance E, and End Results (SEER) Program of the National Cancer Institute. Cancer Stat Facts: Leukemia—Chronic Lymphocytic Leukemia (CLL). **https://seer.cancer.gov/statfacts/html/clyl.html**; 2021.
7. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadié M, Simonetti A, Lutz JM, Berrino F; HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010 Nov 11;116(19):3724-34. doi: 10.1182/blood-2010-05-282632. Epub 2010 Jul 27. Erratum in: Blood. 2011 Mar 24;117(12):3477. PMID: 20664057.
8. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. PMID: 29540348.
9. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol. 2011 Jan;8(1):38-47. doi: 10.1038/nrclinonc.2010.167. Epub 2010 Oct 19. PMID: 20956983.
10. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010 Jan;10(1):37-50. doi: 10.1038/nrc2764. Epub 2009 Dec 3. PMID: 19956173.
11. Fiorcari S, Maffei R, Audrito V, Martinelli S, Ten Hacken E, Zucchini P, Grisendi G, Potenza L, Luppi M, Burger JA, Deaglio S, Marasca R. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 2016 Oct 4;7(40):65968-65981. doi: 10.18632/oncotarget.11782. PMID: 27602755; PMCID: PMC5323207.
12. Bewarder M, Stilgenbauer S, Thurner L, Kaddu-Mulindwa D. Current Treatment Options in CLL. Cancers (Basel). 2021 May 19;13(10):2468. doi: 10.3390/cancers13102468. PMID: 34069354; PMCID: PMC8158749.

Figure 1: The eMedica Device


Figure 2: Patient using the device